SYH2099A is a potent Mat2A protein inhibitor developed as an antineoplastic agent currently under investigation for the treatment of advanced solid tumors and various malignant neoplasms. Its mechanism… Read more













SYH2099A is a potent Mat2A protein inhibitor developed as an antineoplastic agent currently under investigation for the treatment of advanced solid tumors and various malignant neoplasms. Its mechanism of action centers on the inhibition of S-adenosylmethionine synthase isoform 2, a process that disrupts critical methylation pathways required for cancer cell survival. This category provides essential pharmaceutical reference standards, including impurities, metabolites, and stable isotope labelled compounds required for rigorous analytical testing and quality control of this therapeutic candidate. Laboratories utilize these high-quality materials for impurity profiling, method validation, and the development of quantitative assays to ensure the safety and efficacy of final drug formulations. By incorporating these specialized markers into research and development protocols, analytical chemists can accurately identify degradation products and metabolic pathways associated with the inhibitor during clinical and pre-clinical evaluations.